KPMG-INTERNATIONAL
14.10.2020 06:03:13 CEST | Business Wire | Press release
As General Counsel and in-house legal teams contend with the increasing pressures facing their organizations in the wake of COVID-19, there is an urgent need to rethink delivery models and transform legal function operations. While the move to digitize and automate the legal function was already underway before COVID-19, it is now a commercial imperative, and the scope and remit is wider than before as the pandemic situation has intensified the need for organizations to transform.
In response, a Global Legal Operations Transformation Services offering has been launched across KPMG firms, which is designed to provide clients with a wide range of global strategies and cross-border capabilities to help meet the challenges they face.
“I believe KPMG’s Global Legal Operations Transformation Services teams are ‘global,’ both in terms of the geographic coverage but also the strategies offered,” says Stuart Fuller , Head of Global Legal Services, KPMG International. “Practice leaders are senior, experienced, and work together in KPMG firms across Europe, the Americas and the Asia Pacific region. They have a laser focus on results, and they are delivering significant and measurable improvement for legal functions across KPIs, such as productivity, customer satisfaction and quality measures―results that are crucial for organizations in the current climate.”
The KPMG Legal Operations Transformation Services practice leadership team includes Andreas Bong , Nicola Brooks , Philipp Glock , Eric Gorman , Kimberly Tan Majure and David Murray , and with an imminent announcement of a significant further partner hire. These leaders are supported by their team members in country firms, and professionals across the global organization, including MBAs, lawyers, legal technologists, data scientists and specialists in operational excellence. Their diverse and complementary skillsets, and combined experience, unite under KPMG’s global methodology to provide significant value to clients.
“We draw on all of the strengths of KPMG professionals across our firms, not just in legal and technology, but also Lean Six Sigma, Human-Centred Design and Systems Thinking. Together, our organization has achieved a substantial track record of implementing and running the transformation opportunities that we identify,” says Fuller. “KPMG Law is a combination of skills and approaches: we have over 2,700 lawyers in 81 jurisdictions advising on complex advisory and regulatory matters, and large transactions; we also provide global solutions such as business reorganization, global entity management and mass claims, offering an integrated service and advice. The new Legal Operations Transformation Service enables KPMG firms to handle large-scale business in a more efficient and technologically-enabled way and is only the first in a number of capabilities and services that we plan to provide in this space.”
The Legal Operations Transformation Services team brings more than 14 years of credentials and experience in the legal transformation space, with recent and current engagements across multinational organizations in the financial services, asset management, automotive, insurance and consumer goods sectors. In the past two years alone, KPMG firms have delivered cost savings of more than US$200 million across a range of services, including process optimization, automation, contract life cycle management, managed services and productized legal solutions.
David Linke , the Global Head of Tax & Legal Services for KPMG International, says “KPMG firms have a record of innovation and success in Tax Transformation under the banner of ’Tax Reimagined.’ Legal Operations Transformation Services are one of KPMG firms’ leading service offerings. While COVID-19 has accelerated the trends that we were already seeing for legal transformation, the post-COVID world will require legal and compliance teams to be even more efficient, even more engaged with the business and to play a key role in driving the customer experience, revenue and cash conversion cycles. Never has a global and integrated approach to transformation been more in demand than in the current climate. KPMG professionals are focused on bringing the best of our global capabilities, expertise and solutions to legal departments.”
* Important note: Certain member firms of the KPMG global organization, including the US firm, KPMG LLP, do not provide legal services or have KPMG Law service entities. In the US, these Legal Operations Transformation Services will be provided through the Advisory and Tax functions. Some or all the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 147 countries and territories and have more than 219,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such.
KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013006153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom